X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1889) 1889
Book Review (265) 265
Publication (140) 140
Book Chapter (8) 8
Conference Proceeding (3) 3
Magazine Article (2) 2
Data Set (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1776) 1776
humans (1274) 1274
male (1028) 1028
animals (773) 773
sildenafil citrate (589) 589
pharmacology & pharmacy (544) 544
sulfones (505) 505
sulfones - pharmacology (475) 475
female (470) 470
sulfones - pharmacokinetics (382) 382
adult (369) 369
middle aged (364) 364
rats (362) 362
sildenafil (356) 356
sulfones - therapeutic use (324) 324
pharmacokinetics (299) 299
sulfones - administration & dosage (291) 291
purines (286) 286
piperazines - therapeutic use (285) 285
erectile dysfunction (252) 252
erectile dysfunction - drug therapy (240) 240
aged (238) 238
dose-response relationship, drug (238) 238
piperazines - pharmacology (234) 234
mice (231) 231
administration, oral (225) 225
piperazines - pharmacokinetics (219) 219
sulfones - chemistry (205) 205
treatment outcome (185) 185
piperazines - administration & dosage (183) 183
sulfones - adverse effects (180) 180
chemistry, medicinal (179) 179
vardenafil dihydrochloride (166) 166
analysis (165) 165
piperazines - adverse effects (162) 162
phosphodiesterase inhibitors - therapeutic use (160) 160
urology & nephrology (155) 155
double-blind method (153) 153
sulfones - blood (147) 147
drug interactions (141) 141
rats, sprague-dawley (140) 140
abridged index medicus (133) 133
efficacy (127) 127
drug therapy (126) 126
structure-activity relationship (124) 124
time factors (123) 123
tadalafil (121) 121
impotence (118) 118
phosphodiesterase inhibitors - pharmacology (118) 118
toxicology (114) 114
chemistry, analytical (113) 113
double-blind (113) 113
purines - therapeutic use (111) 111
safety (111) 111
phosphodiesterase inhibitors - pharmacokinetics (110) 110
purines - pharmacology (107) 107
area under curve (106) 106
research (105) 105
care and treatment (102) 102
rofecoxib (102) 102
oncology (101) 101
nonsteroidal antiinflammatory drugs (100) 100
sulfones - metabolism (100) 100
vardenafil (99) 99
cross-over studies (98) 98
in-vitro (96) 96
hypertension, pulmonary - drug therapy (95) 95
nitric-oxide (95) 95
half-life (94) 94
purines - administration & dosage (92) 92
medicine & public health (91) 91
metabolism (91) 91
disease models, animal (90) 90
phosphodiesterase inhibitors - adverse effects (90) 90
imidazoles - therapeutic use (89) 89
phosphodiesterase inhibitors - administration & dosage (89) 89
purines - pharmacokinetics (88) 88
biochemistry & molecular biology (87) 87
biological availability (87) 87
chemistry, organic (87) 87
men (87) 87
rats, wistar (87) 87
adolescent (86) 86
sulfones - chemical synthesis (85) 85
pharmacology/toxicology (84) 84
reproducibility of results (84) 84
therapy (84) 84
lactones - therapeutic use (81) 81
tissue distribution (81) 81
vasodilator agents - therapeutic use (81) 81
celecoxib (80) 80
cox-2 inhibitors (80) 80
metabolites (80) 80
chromatography, high pressure liquid (79) 79
health aspects (79) 79
cyclic nucleotide phosphodiesterases, type 5 (78) 78
oral sildenafil (77) 77
pharmacology (77) 77
cardiac & cardiovascular systems (76) 76
cancer (75) 75
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1858) 1858
German (11) 11
Chinese (8) 8
Japanese (5) 5
Spanish (5) 5
French (3) 3
Russian (2) 2
Bulgarian (1) 1
Danish (1) 1
Dutch (1) 1
Hebrew (1) 1
Italian (1) 1
Norwegian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Clinical and Experimental Pharmacology and Physiology, ISSN 0305-1870, 10/2006, Volume 33, Issue 10, pp. 917 - 924
SUMMARY • Non-steroidal anti-inflammatory drugs (NSAIDs) cause renal side-effects. In the present study, we tested the hypothesis that the extent of the renal... 
pharmacokinetics | kidney | non-steroidal anti-inflammatory drugs | cyclo-oxygenase-2 | sodium urinary excretion | cyclo‐oxygenase‐2 | non‐steroidal anti‐inflammatory drugs | Cyclo-oxygenase-2 | Pharmacokinetics | Kidney | Non-steroidal anti-inflammatory drugs | Sodium urinary excretion | GASTROINTESTINAL TOXICITY | PHYSIOLOGY | CYCLOOXYGENASE-2 | RAT | HYPERKALEMIA | PROTEIN-BINDING | MELOXICAM | INTERSPECIES DIFFERENCES | GENTAMICIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | PHARMACOLOGY & PHARMACY | Thiazoles - blood | Area Under Curve | Thiazines - administration & dosage | Thiazines - adverse effects | Sulfones - adverse effects | Male | Thiazoles - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - blood | Thiazoles - adverse effects | Thiazoles - pharmacokinetics | Dose-Response Relationship, Drug | Cyclooxygenase 2 Inhibitors - adverse effects | Sulfonamides - blood | Lactones - blood | Lactones - pharmacokinetics | Sodium - urine | Lactones - administration & dosage | Pyrazoles - blood | Pyrazoles - pharmacokinetics | Sulfones - blood | Placebos - administration & dosage | Pyrazoles - adverse effects | Thiazines - pharmacokinetics | Kidney - drug effects | Administration, Oral | Cyclooxygenase 2 Inhibitors - administration & dosage | Rats | Thiazines - blood | Celecoxib | Lactones - adverse effects | Placebos - pharmacokinetics | Sulfones - pharmacokinetics | Cyclooxygenase 2 Inhibitors - pharmacokinetics | Rats, Sprague-Dawley | Sulfonamides - pharmacokinetics | Pyrazoles - administration & dosage | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Potassium - urine | Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics | Sulfonamides - adverse effects | Sulfonamides - administration & dosage | Sulfones - administration & dosage | Kidney, drug effects | Lactones, adverse effects | Sulfones, administration and dosage | Thiazoles, administration and dosage | Anti-Inflammatory Agents, Non-Steroidal, pharmacokinetics | Anti-Inflammatory Agents, Non-Steroidal, adverse effects | Sodium, urine | Thiazines, blood | Anti-Inflammatory Agents, Non-Steroidal, blood | Lactones, administration and dosage | Cyclooxygenase 2 Inhibitors, adverse effects | Pyrazoles, blood | Sulfonamides, pharmacokinetics | Thiazines, pharmacokinetics | Pyrazoles, administration and dosage | Thiazoles, blood | Sulfonamides, administration and dosage | Cyclooxygenase 2 Inhibitors, administration and dosage | Lactones, pharmacokinetics | Sulfonamides, blood | Cyclooxygenase 2 Inhibitors, pharmacokinetics | Thiazines, adverse effects | Lactones, blood | Thiazoles, adverse effects | Thiazoles, pharmacokinetics | Sulfones, blood | Sulfonamides, adverse effects | Thiazines, administration and dosage | Placebos, pharmacokinetics | Sulfones, pharmacokinetics | Pyrazoles, adverse effects | Placebos, administration and dosage | Potassium, urine | Sulfones, adverse effects | Pyrazoles, pharmacokinetics | Index Medicus
Journal Article
Journal Article
Journal Article
BMC Pharmacology and Toxicology, ISSN 2050-6511, 06/2015, Volume 16, Issue 1, pp. 18 - 18
Journal Article
Journal of Ethnopharmacology, ISSN 0378-8741, 05/2016, Volume 183, pp. 9 - 17
Journal Article
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 8/2013, Volume 208, Issue 3, pp. 512 - 519
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 06/2012, Volume 55, Issue 11, pp. 5188 - 5219
A highly selective series of inhibitors of the class I phosphatidylinositol 3-kinases (PI3Ks) has been designed and synthesized. Starting from the dual... 
MAMMALIAN TARGET | RAPAMYCIN | CROSS-COUPLING REACTIONS | CHEMISTRY, MEDICINAL | PI3K | C-N | PATHWAY | KINASE INHIBITOR | MUTATIONS | CANCER | DISCOVERY | Indazoles - chemical synthesis | Pyrazoles - chemical synthesis | Pyrimidines - chemical synthesis | Humans | Microsomes, Liver - metabolism | Pyridines - pharmacokinetics | Biological Availability | Crystallography, X-Ray | Structure-Activity Relationship | Sulfones - pharmacology | TOR Serine-Threonine Kinases - antagonists & inhibitors | Drug Design | Female | Piperazines - pharmacokinetics | Pyrazoles - pharmacokinetics | Pyrazoles - pharmacology | Sulfones - chemical synthesis | Purines - chemical synthesis | Triazines - pharmacology | Signal Transduction | Purines - pharmacology | Purines - pharmacokinetics | Pyridines - chemical synthesis | Models, Molecular | Rats | Proto-Oncogene Proteins c-akt - physiology | Pyrimidines - pharmacology | Sulfones - pharmacokinetics | Sulfonamides - pharmacology | Class I Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Piperazines - pharmacology | Sulfonamides - pharmacokinetics | Indazoles - pharmacology | Xenograft Model Antitumor Assays | Sulfonamides - chemical synthesis | Animals | Class I Phosphatidylinositol 3-Kinases - physiology | Indazoles - pharmacokinetics | Mice, Nude | Triazines - chemical synthesis | Pyrimidines - pharmacokinetics | Piperazines - chemical synthesis | Mice | Pyridines - pharmacology | Triazines - pharmacokinetics | Index Medicus | DESIGN | NEOPLASMS | BASIC BIOLOGICAL SCIENCES | PHOSPHOTRANSFERASES | IN VIVO | PROTEINS | 60 APPLIED LIFE SCIENCES
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 07/2007, Volume 6, Issue 7, pp. 2012 - 2021
With the development of targeted therapeutics, especially for small-molecule inhibitors, it is important to understand whether the observed in vivo efficacy... 
kinase inhibitor | Pharmacodynamics | pazopanib | angiogenesis | VEGF | TARGET | ONCOLOGY | FACTOR RECEPTORS | EXPRESSION | CANCER | TUMORS | RENAL-CELL CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | Pyrimidines - blood | Humans | Fibroblast Growth Factor 2 - pharmacology | Antineoplastic Agents - administration & dosage | Indazoles - administration & dosage | Sulfones - pharmacology | Neovascularization, Pathologic - pathology | Phosphotyrosine - metabolism | Dose-Response Relationship, Drug | Sulfonamides - blood | Inhibitory Concentration 50 | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Cornea - pathology | Phosphorylation - drug effects | Sulfones - blood | Vascular Endothelial Growth Factor A - pharmacology | Protein Kinase Inhibitors - pharmacokinetics | Pyrimidines - administration & dosage | Pyrimidines - pharmacology | Sulfones - pharmacokinetics | Sulfonamides - pharmacology | Protein Kinase Inhibitors - blood | Sulfonamides - pharmacokinetics | Indazoles - pharmacology | Protein Kinase Inhibitors - administration & dosage | Indazoles - blood | Animals | Indazoles - pharmacokinetics | Cell-Free System | Mice, Nude | Antineoplastic Agents - blood | Cell Line, Tumor | Pyrimidines - pharmacokinetics | Mice | Protein Kinase Inhibitors - pharmacology | Sulfonamides - administration & dosage | Sulfones - administration & dosage | Index Medicus
Journal Article
Journal Article
Journal Article